[BREWER, Richard, SCHREINER, George, F.] 6500 Paseo Padre Parkway Fremont, CA 94555;115 Ericson Road Hillsborough, CA 94010;12274 Leander Drive Los Altos Hills, CA A coated stent or intra-luminal prosthesis containing a MAP kinase inhibitor controls, reduces, or prevents restenosis, inflammation, and complications associated with stent or intra­luminal prosthesis implantation and/or cardiovascular disease.

[R. Richard Goehring, Babu J. Mavunkel, David Y. Liu, George F. Schreiner, Gregory Leudtke, John A. Lewicki] US PA Pipersville The invention is directed to prepare medicaments for treatment of and to methods to treat conditions mediated by kinase using compounds of the formula 1wherein Ar1 and Ph are limited to specific embodiments or wherein the compound of formula (3) is a compound set forth in FIGS. 1A-1I.

[Villarreal, Francisco, Schreiner, George F, Ceballos, Guillermo] 725 San Aleso Avenue Ste 2, Sunnyvale, CA 94085, US The present invention relates to compounds and compositions and their application as pharmaceuticals for treating, preventing, or reversing injury to skeletal or cardiac muscles, for treating or preventing diseases relating to the structure and function of skeletal or cardiac muscle, and for inducing regeneration or restructuring of skeletal or cardiac muscle as a means of treating diseases relating to abnormalities in skeletal or cardiac muscle structure and function in a human or animal subject.

[VILLARREAL, Francisco, TAUB, Pam, R., MAISEL, Alan, S., SCHREINER, George, F., CEBALLOS, Guillermo] 725 San Aleso Avenue, Ste 2 Sunnyvale, CA 94085;967 St. Germain Road Chula Vista, CA 91913;1869 Horseman Lane Rancho Santa Fe, CA 92091;190 Del Mar Shores, #35 Solana Beach, CA 92705;12774 Leander Drive Los Altos Hills, CA 94022;Ave. Instituto Politecnico Nacional # 2126 Edif. 10N dpt. 401, col. Lindavista Medico D.F. 07300 The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.

[FENG, Ying, HIGGINS, Linda, S., KAPOUN, Ann, M., LIU, David, Y., SCHREINER, George, F.] 6500 Paseo Padre Parkway Fremont, CA 94555;853 Markham Terrace Sunnyvale, CA 94086;3610 Louis Road Palo Alto, CA 94303;686 Ehrhorn Avenue Mountain View, CA 94041;201 Ferne Avenue Palo Alto, CA 94306;12774 Leander Drive Los Altos, CA 94022 The invention concerns methods for modulating the ß-adrenergic pathway. In particular, the invention concerns methods for counteracting a pathologic change, such as, for example, a loss in ß-adrenergic sensitivity, in the ß-adrenergic signal transduction pathway by administering an effective amount of a compound capable of inhibiting TGF-ß signaling through a TGF-ß receptor.

[SCHREINER, George F.] 1140 Veterans Blvd. San Francisco, California 94080;c/o RAVEN BIOTECHNOLOGIES, INC. 1140 Veterans Blvd. San Francisco, California 94080 The present invention provides methods and compositions for generating modulators capable of binding to antigens presented by a cell that has been exposed to cellular conditioning. The present invention also includes methods and compositions for the prevention, treatment and diagnosis of disorders using the antigen modulators. The present invention further provides methods for identifying novel molecular targets for the treatment of different disorders.

[Alison Joly, George F. Schreiner, Lawrence W. Stanton, R. Tyler White] US CA San Mateo The invention concerns the use of agonists and antagonists of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.

[Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki] ,Sunnyvale,CA,;,Bridgewater,NJ,;,Los Altos,CA,;,Los Altos Hills,CA,;,Palo Alto,CA,;,Los Gatos,CA, The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R 3 is a noninterfering substituent; each Z is CR 2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R 2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.

[SCHREINER, George, F., HORTON, Darlene, VETTICADEN, Santosh] 6500 PASEO PADRE PARKWAY FREMONT, CA 94555;12774 Leander Drive Los Altos Hills, California 94022;850 De Haro Street San Francisco, California 94107;342 Stanforth Court San Ramon, California 94583 The present invention relates to methods for administration of natriuretic peptide that are especially useful for treatment of a CHF patient. The methods are characterized by the serial and intermittent administration of a composition that provides a dose of natriuretic peptide. The methods of the invention are also useful for the treatment of chronic CHF patients, especially chronically decompensated CHF patients.

[LUM, Robert, T., PFISTER, Jurg, R., SCHOW, Steven, R., WICK, Michael, M., NELSON, Marek, G., SCHREINER, George, F.] 3172 Porter Drive Palo Alto, CA 94304;781 Barron Avenue Palo Alto, CA 94306;1500 Oak Steet Los Altos, CA 94024;204 Mendocino Way Redwood City, CA 94065;16 Beresford Road Chestnut Hill, MA 02146;2690 Park Way Sunol, CA 95051;12774 Leander Drive Los Altos Hills, CA 94022 A substituted N6-oxa, thia, thioxa and azacycloalkyl substituted adenosine derivative of formula (I) and a method for using the composition as an A¿1? heart adenosine receptor. In said formula, R1 is a monocyclic or polycyclic heterocyclic group containing from 3 to 15 atoms, at least one of which is selected from the group consisting of N, O, P and S-(O)o-2 and wherein R1 does not contain an epoxide group.